Curasight initiates pre-clinical studies with uTREAT[®] therapy in head and neck cancer (HNSCC) and neuroendocrine tumors (NET)
Copenhagen, Denmark, 13 October 2022 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announces that it has initiated pre-clinical studies of uPAR targeted radionuclide therapy (uTREAT[®]) in head and neck cancer and in neuroendocrine tumors (NET). Results are expected to be available during 1H 2023.The study starts are in line with Curasight’s expanded strategy to pursue therapy as well as diagnostics within head & neck cancer and neurodocrine tumors (NET), as announced in February this year. The decision to expand into new therapeutic areas is based on the published